Browse BRD7

Summary
SymbolBRD7
Namebromodomain containing 7
Aliases CELTIX1; bromodomain-containing 7; NAG4; 75 kDa bromodomain protein; protein CELTIX-1; Bromodomain-containin ......
Chromosomal Location16q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Isoform 2: Nucleus.
Domain PF00439 Bromodomain
PF12024 Domain of unknown function (DUF3512)
Function

Acts both as coactivator and as corepressor. May play a role in chromatin remodeling. Activator of the Wnt signaling pathway in a DVL1-dependent manner by negatively regulating the GSK3B phosphotransferase activity. Induces dephosphorylation of GSK3B at 'Tyr-216'. Down-regulates TRIM24-mediated activation of transcriptional activation by AR (By similarity). Transcriptional corepressor that down-regulates the expression of target genes. Binds to target promoters, leading to increased histone H3 acetylation at 'Lys-9' (H3K9ac). Binds to the ESR1 promoter. Recruits BRCA1 and POU2F1 to the ESR1 promoter. Coactivator for TP53-mediated activation of transcription of a set of target genes. Required for TP53-mediated cell-cycle arrest in response to oncogene activation. Promotes acetylation of TP53 at 'Lys-382', and thereby promotes efficient recruitment of TP53 to target promoters. Inhibits cell cycle progression from G1 to S phase.

> Gene Ontology
 
Biological Process GO:0000082 G1/S transition of mitotic cell cycle
GO:0006473 protein acetylation
GO:0006475 internal protein amino acid acetylation
GO:0007346 regulation of mitotic cell cycle
GO:0010948 negative regulation of cell cycle process
GO:0016055 Wnt signaling pathway
GO:0016570 histone modification
GO:0016573 histone acetylation
GO:0018205 peptidyl-lysine modification
GO:0018393 internal peptidyl-lysine acetylation
GO:0018394 peptidyl-lysine acetylation
GO:0031056 regulation of histone modification
GO:0031058 positive regulation of histone modification
GO:0035065 regulation of histone acetylation
GO:0035066 positive regulation of histone acetylation
GO:0043543 protein acylation
GO:0044770 cell cycle phase transition
GO:0044772 mitotic cell cycle phase transition
GO:0044843 cell cycle G1/S phase transition
GO:0045786 negative regulation of cell cycle
GO:0045930 negative regulation of mitotic cell cycle
GO:0072331 signal transduction by p53 class mediator
GO:0198738 cell-cell signaling by wnt
GO:1901796 regulation of signal transduction by p53 class mediator
GO:1901983 regulation of protein acetylation
GO:1901985 positive regulation of protein acetylation
GO:1901987 regulation of cell cycle phase transition
GO:1901988 negative regulation of cell cycle phase transition
GO:1901990 regulation of mitotic cell cycle phase transition
GO:1901991 negative regulation of mitotic cell cycle phase transition
GO:1902275 regulation of chromatin organization
GO:1902806 regulation of cell cycle G1/S phase transition
GO:1902807 negative regulation of cell cycle G1/S phase transition
GO:1905269 positive regulation of chromatin organization
GO:2000045 regulation of G1/S transition of mitotic cell cycle
GO:2000134 negative regulation of G1/S transition of mitotic cell cycle
GO:2000756 regulation of peptidyl-lysine acetylation
GO:2000758 positive regulation of peptidyl-lysine acetylation
Molecular Function GO:0002039 p53 binding
GO:0003713 transcription coactivator activity
GO:0003714 transcription corepressor activity
GO:0008134 transcription factor binding
GO:0042393 histone binding
GO:0070577 lysine-acetylated histone binding
Cellular Component GO:0070603 SWI/SNF superfamily-type complex
GO:0090544 BAF-type complex
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-5633007: Regulation of TP53 Activity
R-HSA-6804758: Regulation of TP53 Activity through Acetylation
R-HSA-3700989: Transcriptional Regulation by TP53
Summary
SymbolBRD7
Namebromodomain containing 7
Aliases CELTIX1; bromodomain-containing 7; NAG4; 75 kDa bromodomain protein; protein CELTIX-1; Bromodomain-containin ......
Chromosomal Location16q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between BRD7 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolBRD7
Namebromodomain containing 7
Aliases CELTIX1; bromodomain-containing 7; NAG4; 75 kDa bromodomain protein; protein CELTIX-1; Bromodomain-containin ......
Chromosomal Location16q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of BRD7 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: -2.94; FDR: 0.03680 Resistant to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolBRD7
Namebromodomain containing 7
Aliases CELTIX1; bromodomain-containing 7; NAG4; 75 kDa bromodomain protein; protein CELTIX-1; Bromodomain-containin ......
Chromosomal Location16q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of BRD7 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.3260.124
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.6570.754
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0840.957
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91601
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.020.993
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.0260.992
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0890.801
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.1540.928
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.010.996
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.240.88
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.2890.908
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0330.527
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of BRD7 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.72.711
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.73.40.31
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolBRD7
Namebromodomain containing 7
Aliases CELTIX1; bromodomain-containing 7; NAG4; 75 kDa bromodomain protein; protein CELTIX-1; Bromodomain-containin ......
Chromosomal Location16q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of BRD7. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolBRD7
Namebromodomain containing 7
Aliases CELTIX1; bromodomain-containing 7; NAG4; 75 kDa bromodomain protein; protein CELTIX-1; Bromodomain-containin ......
Chromosomal Location16q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of BRD7. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by BRD7.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolBRD7
Namebromodomain containing 7
Aliases CELTIX1; bromodomain-containing 7; NAG4; 75 kDa bromodomain protein; protein CELTIX-1; Bromodomain-containin ......
Chromosomal Location16q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of BRD7. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolBRD7
Namebromodomain containing 7
Aliases CELTIX1; bromodomain-containing 7; NAG4; 75 kDa bromodomain protein; protein CELTIX-1; Bromodomain-containin ......
Chromosomal Location16q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of BRD7 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolBRD7
Namebromodomain containing 7
Aliases CELTIX1; bromodomain-containing 7; NAG4; 75 kDa bromodomain protein; protein CELTIX-1; Bromodomain-containin ......
Chromosomal Location16q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between BRD7 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolBRD7
Namebromodomain containing 7
Aliases CELTIX1; bromodomain-containing 7; NAG4; 75 kDa bromodomain protein; protein CELTIX-1; Bromodomain-containin ......
Chromosomal Location16q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting BRD7 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.